Ultragenyx Faces Securities Class Actions Over Setrusumab Phase III Fracture Data

Allegations Focus on Setrusumab Trial Results and Company Disclosures

Ultragenyx Pharmaceutical faces consolidated securities class action claims alleging the company misled investors about the clinical prospects of setrusumab (UX143) in treating osteogenesis imperfecta (OI). Plaintiffs contend Ultragenyx repeatedly promotes confidence that the antibody would reduce patients’ annualized fracture rates while downplaying or concealing data that undermine that claim. The suits point to a gap between increases in bone mineral density observed in trials and the drug’s failure to demonstrate a corresponding reduction in clinical fractures.

The complaints center on Ultragenyx’s Phase III Orbit and Cosmic studies, which the company discloses do not achieve statistical significance on their primary endpoints for reducing annualized clinical fracture rates versus placebo or bisphosphonates. Plaintiffs assert management overstated the likelihood that study designs would demonstrate fracture reduction and did not adequately disclose risks that the observed bone density gains would not translate into fewer fractures. Regulators and clinicians assess both surrogate endpoints such as bone density and hard clinical outcomes like fracture frequency when judging therapies for rare bone disorders, and the litigation underscores the tensions when surrogate gains do not align with clinical benefit.

Ultragenyx’s December disclosure of the Phase III results prompts scrutiny of the company’s communications about setrusumab as it advances other development and regulatory plans for OI. The cases highlight broader industry challenges in demonstrating meaningful clinical endpoints for rare disease treatments and the reputational and legal risks firms face when trial outcomes diverge from prior public representations. Observers note that clarity on trial design, endpoint selection and the clinical relevance of surrogate measures is increasingly central to company-investigator discussions and investor communications in biotech.

Court Timeline, Potential Lead Plaintiffs

Two law firms — Rosen Law Firm and The Gross Law Firm — announce separate class action notices covering purchasers of Ultragenyx common stock from Aug. 3, 2023 through Dec. 26, 2025. Both set April 6, 2026 as the deadline for prospective lead plaintiffs to move the court for appointment, a procedural step that determines who will steer the litigation on behalf of the class.

Firms’ Outreach and Claims

The firms describe contingency-fee representations and invite affected shareholders to register for potential participation and monitoring, while emphasizing prior experience in securities litigation. Their notices reiterate allegations that Ultragenyx’s public statements materially misrepresented the link between bone density increases and fracture reductions in the Phase III programs.